Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients

British Journal of Clinical Pharmacology

Volumn 59, Issue 2, 2005, Pages 183-188

  Jullien, V ^a   Treluyer J M ^a   Chappuy, H ^a   Dimet, J ^a   Rey, E ^a   Dupin, N ^a   Salmon, D ^a   Pons, G ^a   Urien, S ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Abacavir; Adults; Bodyweight; HIV; Population pharmacokinetics

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DATA ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; PRIORITY JOURNAL; STATISTICAL MODEL;

EID: 13444274556     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02259.x     Document Type: Article

References (21)

1. Harris M, Back D, Kewn S, Jutha S, Marina R, Montaner JS. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS 2002; 16 (8): 1196-7.
2. Saag MS, Sonnerborg A, Torres RA, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clin Team AIDS 1998; 12 (16): F203-9.
3. Staszewski S, Katlama C, Harrer T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998; 12 (16): F197-202.
4. Horton CM, Dudley MN, Kaul S, et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995; 39 (10): 2309-15.
5. Zhou XJ, Sheiner LB, D'Aquila RT, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators Antimicrob Agents Chemother 1999; 43 (1): 121-8.
6. Weller S, Radomski KM, Lou Y, Stein DS. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2000; 44 (8): 2052-60.
7. Beal SL, Sheiner LB. NONMEM user's guide. San Francisco: NONMEM Project Group, University of California at San Francisco; 1991.
8. Parke J, Charles BG. Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. Eur J Clin Pharmacol 2000; 56 (6-7): 481-7.
9. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Meth Programs Biomed 1999; 59 (1): 19-29.
10. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28 (5): 2002, 481-504. Erratum. In: J Pharmacokinet Pharmacodyn 2002; 29 (3): 309.
11. Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 1999; 43 (3): 603-8.
12. McDowell JA, Lou Y, Symonds WS, Stein DS. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000; 44 (8): 2061-7.
13. McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. Pharmacokinetics of [(14) C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43 (12): 2855-61.
14. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36 (4): 289-304.
15. McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000; 44 (6): 1686-90.
16. Reinach B, de Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R. Comparative effect of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 1999; 121 (1): 37-48.
17. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interaction with nevirapine. JAIDS 2003; 34(Suppl 1): S8-S14.
18. Resetar A, Minick D, Spector T. Glucuronidation of 3′-azido- 3′-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem Pharmacol 1991; 42 (3): 559-68.
19. Becher F, Landman R, Mboup S, et al. Monitoring of didanosine and stavudine intracellular triphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004; 18: 181-7.
20. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14 (10): 1333-9.
21. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16 (10): 1341-9. Erratum in: AIDS, 2002; 16 (12): 1708.